Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model.

[1]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[2]  D. Haines,et al.  Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. , 2009, Cancer research.

[3]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[4]  A. Krasnitz,et al.  An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.

[5]  F. Zunino,et al.  The human homolog of fission yeast Rad17 is implicated in tumor growth. , 2008, Cancer letters.

[6]  A. Krasnitz,et al.  DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. , 2008, Genes & development.

[7]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[8]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[9]  Michael R. Green,et al.  Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.

[10]  J. Califano,et al.  Downregulation of RAD17 in head and neck cancer , 2008, Head & neck.

[11]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[12]  W. Gu,et al.  Non-transcriptional control of DNA replication by c-Myc , 2007, Nature.

[13]  K. Cowan,et al.  Irradiation-induced G2/M checkpoint response requires ERK1/2 activation , 2007, Oncogene.

[14]  S. Sharan,et al.  Resolving RAD51C function in late stages of homologous recombination , 2007, Cell Division.

[15]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[16]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[17]  S. Elledge,et al.  Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. , 2006, Molecular cell.

[18]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[19]  Yanhui Hu,et al.  Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. , 2006, Journal of proteome research.

[20]  R. Clarke,et al.  Aberrant Activation of Notch Signaling in Human Breast Cancer , 2006 .

[21]  John T. Powers,et al.  ATM promotes apoptosis and suppresses tumorigenesis in response to Myc , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Christopher J Kemp,et al.  Tumor suppressor genetics. , 2005, Carcinogenesis.

[23]  A. Berns,et al.  Retroviral insertional mutagenesis: past, present and future , 2005, Oncogene.

[24]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[25]  S. Lowe,et al.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors , 2005, Nature Genetics.

[26]  Dieter Huesken,et al.  Design of a genome-wide siRNA library using an artificial neural network , 2005, Nature Biotechnology.

[27]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[28]  L. Chin,et al.  A Genetic Screen for Candidate Tumor Suppressors Identifies REST , 2005, Cell.

[29]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[30]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Patrick Maisonneuve,et al.  Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis , 2004, The Journal of cell biology.

[32]  B. Beverloo,et al.  Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage‐dependent recombination , 2004, The EMBO journal.

[33]  J. Rosen,et al.  Chk1 is haploinsufficient for multiple functions critical to tumor suppression. , 2004, Cancer cell.

[34]  S. Lowe,et al.  Suppression of tumorigenesis by the p53 target PUMA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[36]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[37]  D. Felsher,et al.  Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Elledge,et al.  Genomic instability and endoreduplication triggered by RAD17 deletion. , 2003, Genes & development.

[39]  Patrick J. Paddison,et al.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.

[40]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[41]  Richard A. Lang,et al.  Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. J. Kent,et al.  BLAT--the BLAST-like alignment tool. , 2002, Genome research.

[43]  S. Lowe,et al.  Apoptosis and chemoresistance in transgenic cancer models , 2002, Journal of Molecular Medicine.

[44]  Xiao-Fan Wang,et al.  ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses , 2001, Nature.

[45]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[46]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[47]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[48]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[49]  D. Woods,et al.  Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.

[50]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[51]  A. Parker,et al.  Identification of a Human Homologue of theSchizosaccharomyces pombe rad17 + Checkpoint Gene* , 1998, The Journal of Biological Chemistry.

[52]  C. Marshall,et al.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1 , 1998, Nature.

[53]  R. Fleischmann,et al.  DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus , 1997, Nature Genetics.

[54]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[55]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[56]  D. Baltimore,et al.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. , 1996, Genes & development.

[57]  J. Bos,et al.  Involvement of p21ras in activation of extracellular signal-regulated kinase 2 , 1992, Nature.

[58]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[59]  Takeshi Suzuki,et al.  RTCGD: retroviral tagged cancer gene database , 2004, Nucleic Acids Res..